Tracy Hooper
Family · Chatsworth, GANPI 1619962206
Payments from drug & device makers
Across 298 payments — averaging $19.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$796
- Amgen$572
- Pfizer$560
- Novo Nordisk$462
- Sanofi-aventis U.S. LLC$341
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$334
- plus $3K from 30 others
What the payments were for
- Food & beverage$5,733100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 47 | $796 |
| Amgen | 35 | $572 |
| Pfizer | 28 | $560 |
| Novo Nordisk | 28 | $462 |
| Sanofi-aventis U.S. LLC | 18 | $341 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 18 | $334 |
| AstraZeneca | 15 | $305 |
| Bayer | 13 | $285 |
| GSK | 14 | $233 |
| Sumitomo Pharma America, Inc. | 5 | $183 |
| Medtronic | 2 | $183 |
| Axsome Therapeutics, Inc. | 4 | $169 |
| Astellas Pharma US Inc | 7 | $145 |
| Lilly USA, LLC | 8 | $120 |
| Boehringer Ingelheim | 6 | $117 |
| Merck | 6 | $90 |
| Shield Therapeutics Inc | 4 | $86 |
| Esperion Therapeutics, Inc. | 5 | $84 |
| Amarin Pharma, Inc. | 4 | $78 |
| Xeris Pharmaceuticals, Inc. | 4 | $77 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $73 |
| Dexcom, Inc. | 2 | $67 |
| Abbott | 4 | $58 |
| Mylan Specialty L.p. | 2 | $55 |
| Johnson & Johnson(2 entities) | 2 | $39 |
| Biohaven Pharmaceuticals, Inc. | 2 | $33 |
| Lundbeck LLC | 1 | $30 |
| Corcept Therapeutics | 1 | $25 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $20 |
| Genentech USA, Inc. | 3 | $18 |
| Optinose US, Inc. | 1 | $18 |
| Idorsia Pharmaceuticals US Inc | 1 | $17 |
| Kowa Pharmaceuticals America, Inc. | 1 | $17 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $15 |
| Inspire Medical Systems, Inc. | 1 | $15 |
| Exact Sciences | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,733 in reported general payments places this provider in the 90th percentile of 6,258 family providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 424 | $440,431 |
| FarxigaDapagliflozin Propanediol | 236 | $217,451 |
| EliquisApixaban | 163 | $156,189 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 172 | $154,006 |
| MounjaroTirzepatide | 122 | $147,650 |
| OtezlaApremilast | 21 | $100,922 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 96 | $90,295 |
| RybelsusSemaglutide | 45 | $75,658 |
| LinzessLinaclotide | 81 | $61,511 |
| JardianceEmpagliflozin | 65 | $59,821 |
| Tresiba Flextouch U-100Insulin Degludec | 100 | $53,753 |
| Tresiba Flextouch U-200Insulin Degludec | 48 | $48,765 |
| MyrbetriqMirabegron | 58 | $44,763 |
| VraylarCariprazine Hcl | 30 | $43,853 |
| TrulicityDulaglutide | 21 | $36,346 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $462 | $516,089469 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $305 | $266,003303 claims |
| Lilly USA, LLCMounjaro, Trulicity | $120 | $183,997143 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $233 | $164,236195 claims |
| PfizerEliquis | $560 | $156,189163 claims |
| Boehringer IngelheimJardiance, Combivent Respimat, Tradjenta, Spiriva Respimat, Synjardy Xr | $117 | $131,262144 claims |
| AbbVieLinzess, Vraylar, Namzaric | $796 | $123,782129 claims |
| AmgenOtezla | $572 | $100,92221 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $341 | $90,29596 claims |
| MerckJanuvia, Janumet, Belsomra | $90 | $78,04876 claims |
| Astellas Pharma US IncMyrbetriq | $145 | $44,76358 claims |
| Johnson & JohnsonXarelto, Invokana | $39 | $31,49829 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 6,258 family providers in Georgia.
Other family in Chatsworth
- Allie McAllisterMarietta$299K
- Tonita WashingtonLawrenceville$153K
- Erin HenryLawrenceville$135K
- Trisha RomanPeachtree City$134K
- Lori ReedMarietta$106K
- Julia BranchCumming$102K
- Hannah BanachWaycross$85K
- Morgan GroothandEvans$81K
- Anna Carolina WrightLilburn$69K
- Jessica FeehanCanton$51K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.